According to NICE Technology Appraisal 875 , semaglutide 2.4 mg (Wegovy) may be considered for adults with a BMI of at least 35 kg/m, or at least 30 kg/m with at least one weight-related comorbidity
Document your actual injection times during travel to share with your healthcare team at your next check-in
patients should be advised to seek immediate medical attention for severe, persistent abdominal pain Gallbladder disease : cholelithiasis and cholecystitis have been reported with GLP-1 receptor agonists [11] [22] Diabetic retinopathy complications : particularly in patients with pre-existing retinopathy who experience rapid improvement in glucose control Common adverse effects of Januvia include: Upper respiratory tract infections and nasopharyngitis Headache and gastrointestinal disturbances (though generally milder than with GLP-1 agonists) Rare but serious risks : acute pancreatitis, severe joint pain, hypersensitivity reactions, and bullous pemphigoid (a serious skin condition) When used together, there is a theoretical increased risk of gastrointestinal side effects , particularly nausea, as both medications influence gut hormone pathways
But recognizing UTI symptoms can be tricky when you are already experiencing semaglutide side effects that create overlapping sensations
Stop the medication immediately and seek emergency care if you experience severe upper abdominal pain, nausea, vomiting, or elevated pancreatic enzymes
This will depend on your current situation and whether our clinical team determines which dose is safe for you to transition to
)
.webp)
